Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 638 drug-target rows in SSL view, for TSG = CUX1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib CUX1 PDGFRB 7
sunitinib CUX1 KIT 7
sunitinib CUX1 PDGFRA 7
sunitinib CUX1 CSF1R 7
docetaxel, thalidomide CUX1 ORM1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CUX1 PDGFRB 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CUX1 RET 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CUX1 KIT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CUX1 NTRK1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CUX1 PDGFRA 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab CUX1 ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) CUX1 PDGFRB 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) CUX1 RET 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) CUX1 KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) CUX1 NTRK1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) CUX1 PDGFRA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) CUX1 ABL1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CUX1 PDGFRB 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CUX1 RET 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CUX1 KIT 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CUX1 NTRK1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CUX1 PDGFRA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CUX1 ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CUX1 CSF1R 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CUX1 BCR 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan CUX1 TOP1MT 3
lurbinectedin, irinotecan CUX1 TOP1MT 3
pembrolizumab, belzutifan, lenvatinib CUX1 RET 3
pembrolizumab, belzutifan, lenvatinib CUX1 KIT 3
pembrolizumab, belzutifan, lenvatinib CUX1 PDGFRA 3
avapritinib CUX1 KIT 7
nintedanib CUX1 PDGFRB 7
nintedanib CUX1 PDGFRA 7
pazopanib CUX1 PDGFRB 7
pazopanib CUX1 KIT 7
pazopanib CUX1 PDGFRA 7
regorafenib CUX1 PDGFRB 7
regorafenib CUX1 RET 7
regorafenib CUX1 KIT 7
regorafenib CUX1 PDGFRA 7
regorafenib CUX1 ABL1 7
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel CUX1 RET 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel CUX1 ABL1 2
apatinib, irinotecan CUX1 TOP1MT 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan CUX1 TOP1MT 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine CUX1 TOP1MT 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CUX1 PDGFRB 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CUX1 KIT 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CUX1 ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CUX1 BCR 2
cabozantinib CUX1 RET 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib CUX1 RET 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery CUX1 TOP1MT 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib CUX1 PDGFRB 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib CUX1 RET 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib CUX1 NTRK1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib CUX1 DDR1 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a CUX1 RET 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a CUX1 KIT 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a CUX1 PDGFRA 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide CUX1 TOP1MT 2
irinotecan, capecitabine CUX1 TOP1MT 2
irinotecan, docetaxel CUX1 TOP1MT 2
lenvatinib, pembrolizumab CUX1 RET 2
lenvatinib, pembrolizumab CUX1 KIT 2
lenvatinib, pembrolizumab CUX1 PDGFRA 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate CUX1 RET 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate CUX1 KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate CUX1 PDGFRA 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab CUX1 TOP1MT 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a CUX1 RET 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a CUX1 KIT 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a CUX1 PDGFRA 2
nintedanib, pembrolizumab CUX1 PDGFRB 2
nintedanib, pembrolizumab CUX1 PDGFRA 2
pembrolizumab, lenvatinib CUX1 RET 2
pembrolizumab, lenvatinib CUX1 KIT 2
pembrolizumab, lenvatinib CUX1 PDGFRA 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu CUX1 RET 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu CUX1 KIT 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu CUX1 PDGFRA 2
pembrolizumab, paclitaxel, docetaxel, irinotecan CUX1 TOP1MT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin CUX1 RET 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin CUX1 KIT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin CUX1 PDGFRA 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery CUX1 RET 2
regorafenib CUX1 NTRK1 2
regorafenib, laboratory biomarker analysis CUX1 PDGFRB 2
regorafenib, laboratory biomarker analysis CUX1 RET 2
regorafenib, laboratory biomarker analysis CUX1 KIT 2
regorafenib, laboratory biomarker analysis CUX1 NTRK1 2
regorafenib, laboratory biomarker analysis CUX1 PDGFRA 2
regorafenib, laboratory biomarker analysis CUX1 ABL1 2
sorafenib, administered orally, ct/mri CUX1 PDGFRB 2
sorafenib, administered orally, ct/mri CUX1 RET 2
sorafenib, administered orally, ct/mri CUX1 KIT 2
thalidomide CUX1 ORM1 2
topotecan CUX1 TOP1MT 2
bosutinib CUX1 ABL1 7
entrectinib CUX1 NTRK1 7
ponatinib CUX1 ABL1 7
ponatinib CUX1 BCR 7
selpercatinib CUX1 RET 7
sorafenib CUX1 PDGFRB 7
sorafenib CUX1 RET 7
sorafenib CUX1 KIT 7
sulfasalazine CUX1 PTGS1 7
vandetanib CUX1 RET 7
5 fluorouracil, leucovorin, irinotecan, oxaliplatin CUX1 TOP1MT 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan CUX1 TOP1MT 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf CUX1 TOP1MT 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CUX1 PDGFRB 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CUX1 KIT 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CUX1 ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CUX1 BCR 1
afatinib, irinotecan CUX1 TOP1MT 1
aldoxorubicin, topotecan CUX1 TOP1MT 1
amrubicin, topotecan CUX1 TOP1MT 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel CUX1 TOP1MT 1
at-101, topotecan CUX1 TOP1MT 1
atezolizumab, cabozantinib CUX1 RET 1
atezolizumab, tivozanib CUX1 PDGFRB 1
atezolizumab, tivozanib CUX1 KIT 1
atezolizumab, tivozanib CUX1 PDGFRA 1
avapritinib, midazolam CUX1 KIT 1
avastin, temozolomide, irinotecan CUX1 TOP1MT 1
avastin, temozolomide, radiation therapy (xrt), irinotecan CUX1 TOP1MT 1
avelumab, irinotecan, paclitaxel, best supportive care (bsc) CUX1 TOP1MT 1
azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine CUX1 TOP1MT 1
bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 CUX1 TOP1MT 1
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil CUX1 TOP1MT 1
berzosertib, computed tomography assisted biopsy, endoscopic biopsy, irinotecan, magnetic resonance imaging CUX1 TOP1MT 1
bevacizumab [avastin], irinotecan, temozolomide CUX1 TOP1MT 1
bevacizumab, dasatinib, placebo CUX1 PDGFRB 1
bevacizumab, dasatinib, placebo CUX1 KIT 1
bevacizumab, dasatinib, placebo CUX1 ABL1 1
bevacizumab, dasatinib, placebo CUX1 BCR 1
bevacizumab, irinotecan CUX1 TOP1MT 1
bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging CUX1 TOP1MT 1
bevacizumab, temozolomide, radiation therapy (xrt), topotecan CUX1 TOP1MT 1
bi 764532, topotecan, single agent chemotherapy CUX1 TOP1MT 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib CUX1 PDGFRB 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib CUX1 KIT 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib CUX1 PDGFRA 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib CUX1 CSF1R 1
biopsy, biospecimen collection, computed tomography, endoscopic ultrasound, fluorouracil, irinotecan, leucovorin, lymph node biopsy, magnetic resonance imaging, oxaliplatin, pembrolizumab, photodynamic therapy, positron emission tomography, questionnaire administration, verteporfin CUX1 TOP1MT 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging CUX1 PDGFRB 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging CUX1 RET 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging CUX1 KIT 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging CUX1 PDGFRA 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging CUX1 CSF1R 1
biopsy, biospecimen collection, computed tomography, larotrectinib, magnetic resonance imaging CUX1 NTRK1 1
biospecimen collection, computed tomography, core biopsy, fluorouracil, irinotecan, leucovorin, leucovorin calcium, oxaliplatin, quemliclustat, zimberelimab CUX1 TOP1MT 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography CUX1 PDGFRB 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography CUX1 RET 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography CUX1 KIT 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography CUX1 PDGFRA 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography CUX1 CSF1R 1
biospecimen collection, lidocaine, resection CUX1 ORM1 1
bl-b01d1, irinotecan, paclitaxel, docetaxel CUX1 TOP1MT 1
bl-b01d1, topotecan CUX1 TOP1MT 1
bnt327 dose level 1 (dl1), bnt327 dose level 2 (dl2), etoposide, carboplatin, paclitaxel, topotecan CUX1 TOP1MT 1
bortezomib, irinotecan CUX1 TOP1MT 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab CUX1 PDGFRB 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab CUX1 PDGFRA 1
cabozantinib, durvalumab, tremelimumab CUX1 RET 1
cabozantinib, nivolumab CUX1 RET 1
cabozantinib, pembrolizumab CUX1 RET 1
camrelizumab, docetaxel, irinotecan CUX1 TOP1MT 1
camrelizumab, irinotecan, paclitaxel, paclitaxel-albumin, docetaxel, anlotinib CUX1 TOP1MT 1
capecitabine, oxaliplatin, irinotecan CUX1 TOP1MT 1
carboplatin, irinotecan CUX1 TOP1MT 1
carboxylesterase-expressing allogeneic neural stem cells, irinotecan, irinotecan hydrochloride, laboratory biomarker analysis, pharmacological study CUX1 TOP1MT 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin CUX1 PTGS1 1
celecoxib, cyclophosphamide, etoposide, thalidomide CUX1 ORM1 1
celecoxib, isotretinoin, temozolomide, thalidomide CUX1 ORM1 1
celecoxib, temozolomide, thalidomide, adjuvant therapy CUX1 ORM1 1
cetuximab, bevacizumab, irinotecan CUX1 TOP1MT 1
cetuximab, irinotecan, oxaliplatin, uft CUX1 TOP1MT 1
chlorpromazine, temozolomide, radiation therapy CUX1 ORM1 1
cisplatin, fluorouracil, gemcitabine, irinotecan, leucovorin, nab-paclitaxel, oxaliplatin, radiation therapy CUX1 TOP1MT 1
cisplatin, gleevec™, irinotecan CUX1 TOP1MT 1
cisplatin, irinotecan, capecitabine CUX1 TOP1MT 1
cisplatin, pemetrexed disodium, sorafenib CUX1 PDGFRB 1
cisplatin, pemetrexed disodium, sorafenib CUX1 RET 1
cisplatin, pemetrexed disodium, sorafenib CUX1 KIT 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride CUX1 PDGFRB 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride CUX1 KIT 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride CUX1 ABL1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride CUX1 BCR 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method CUX1 PDGFRB 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method CUX1 KIT 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method CUX1 ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method CUX1 BCR 1
dasatinib, laboratory biomarker analysis, physiologic testing CUX1 PDGFRB 1
dasatinib, laboratory biomarker analysis, physiologic testing CUX1 KIT 1
dasatinib, laboratory biomarker analysis, physiologic testing CUX1 ABL1 1
dasatinib, laboratory biomarker analysis, physiologic testing CUX1 BCR 1
dasatinib, mfolfox6 CUX1 PDGFRB 1
dasatinib, mfolfox6 CUX1 KIT 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.